[1]李群真,李 军,郭树繁,等.辛芷通窍颗粒对慢性鼻窦炎小鼠鼻窦黏膜的保护机制研究[J].陕西中医,2024,(3):318-322.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.006]
　LI Qunzhen,LI Jun,GUO Shufan,et al.Protective effects and mechanisms of Xinzhi Tongqiao granules on nasal sinus mucosa in chronic rhinosinusitis mice model[J].,2024,(3):318-322.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.006]
点击复制

辛芷通窍颗粒对慢性鼻窦炎小鼠鼻窦黏膜的保护机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
318-322
栏目:
基础研究
出版日期:
2024-03-05

文章信息/Info

Title:
Protective effects and mechanisms of Xinzhi Tongqiao granules on nasal sinus mucosa in chronic rhinosinusitis mice model
作者:
李群真; 李 军; 郭树繁; 燕 茹; 董学娜; 马凤梅
(河北省中医院耳鼻喉科,河北 石家庄 050011)
Author(s):
LI Qunzhen; LI Jun; GUO Shufan; YAN Ru; DONG Xuena; MA Fengmei
(Department of Otolaryngology,Hebei Provincial Hospital of Traditional Chinese Medicine,Shijiazhuang 050011,China)
关键词:
慢性鼻窦炎;  辛芷通窍颗粒;  胞内高迁移率族蛋白B1;  NOD样受体蛋白3;  炎症因子
Keywords:
Chronic rhinosinusitis;  Xinzhi Tongqiao granules;  High mobility group box 1;  NOD-like receptor protein 3;  Inflammatory factor
分类号:
R 765.4
DOI:
DOI:10.3969/j.issn.1000-7369.2024.03.006
文献标志码:
A
摘要:
目的:探讨辛芷通窍颗粒对慢性鼻窦炎(CRS)小鼠鼻窦黏膜的保护作用及相关机制。方法:将50只C57BL/6J小鼠随机分为假手术组、模型组、辛芷通窍低剂量组、辛芷通窍中剂量组、辛芷通窍高剂量组。采用开放上颌窦后接种3型荚膜型肺炎链球菌的方法建立CRS小鼠模型。辛芷通窍低剂量组予以1.4 g/kg辛芷通窍颗粒灌胃、辛芷通窍中剂量组予以2.8 g/kg辛芷通窍颗粒灌胃、辛芷通窍高剂量组予以5.6 g/kg辛芷通窍颗粒灌胃治疗。利用ELISA法检测小鼠外周血炎症因子水平; 采用RT-qPCR、Western blot法检测鼻窦黏膜中相关因子表达。结果:与假手术组相比,辛芷通窍低剂量组、辛芷通窍中剂量组、辛芷通窍高剂量组小鼠外周血炎症因子水平明显低于给药前,且窦黏膜组织中TNF-α、IL-6、IL-10、IL-16、IFN-γ的mRNA及蛋白相对表达低于模型组,差异有统计学意义(均P<0.05)。与模型组相比,辛芷通窍低剂量组、辛芷通窍中剂量组、辛芷通窍高剂量组小鼠鼻窦黏膜组织中HMGB1、NLRP3、ASC、Cleaved caspase-1 蛋白表达降低,差异有统计学意义(均P<0.05)。结论:辛芷通窍颗粒呈剂量依赖性地抑制HMGB1/NLRP3信号通路激活,抑制CRS小鼠鼻窦黏膜炎症水平。
Abstract:
Objective:To explore protective effect and mechanism of Xinzhi Tongqiao granules on nasal sinus mucosa of chronic rhinosinusitis(CRS)mice.Methods:Fifty C57BL/6J mice were randomly divided into sham operation group,model group,low-dose group of Xinzhi Tongqiao,medium-dose groupof Xinzhi Tongqiao,and high-dose group of Xinzhi Tongqiao.The CRS mouse model were established by intranasal instillation of three types of encapsulated pneumococci after open maxillary sinus surgery.The low-dose group of Xinzhi Tongqiao were treated with 1.4 g/kg of Xinzhi Tongqiao granules,the medium-dose group of Xinzhi Tongqiao with 2.8 g/kg of Xinzhi Tongqiao granules,and the high-dose group of Xinzhi Tongqiao with 5.6 g/kg of Xinzhi Tongqiao granules.The expression levels of inflammatory factors in peripheral blood and relevant factors in nasal sinus mucosa were measured by RT-qPCR Western blot.Results:Compared with the sham operation group,the levels of inflammatory factors in the peripheral blood of the low-dose group of Xinzhi Tongqiao,the medium-dose group of Xinzhi Tongqiao,and the high-dose group of Xinzhi Tongqiao were significantly lower than those before administration,and the relative expression levels of TNF-α,IL-6,IL-10,IL-16,and IFN-γ mRNA and protein in the sinus mucosa were significantly lower than those in the model group,difference statistically significant(all P<0.05).Compared with the model group,the expression levels of HMGB1,NLRP3,ASC,and Cleaved caspase-1 proteins in the nasal sinus mucosa of the low-dose group of Xinzhi Tongqiao,the medium-dose group of Xinzhi Tongqiao,and the high-dose group of Xinzhi Tongqiao were lower,difference statistically significant(all P<0.05).Conclusion:Xinzhi Tongqiao granules can dose-dependently inhibit activation of HMGB1/NLRP3 signaling pathway and suppress level of nasal sinus mucosal inflammation in CRS mice.

参考文献/References:

[1] 刘爽,马文成,隋强,等.鼻窦炎口服液联合布地奈德超声雾化鼻吸入对慢性鼻-鼻窦炎术后患者黏膜形态和功能转归的影响[J].陕西中医,2020,41(7):929-931,944.
[2] 陈艳丽,宋鹏,刘接威,等.慢性鼻窦炎伴鼻息肉患者鼻腔黏膜组织白细胞介素-17A表达特征及检测临床意义[J].陕西医学杂志,2022,51(5):612-616.
[3] KATO A,PETERS A T,STEVENS W W,et al.Endotypes of chronic rhinosinusitis:Relationships to disease phenotypes pathogenesis clinical findings and treatment approaches[J].Allergy,2022,77(3):812-826.
[4] 陈璀璀,李永磊,芦二永.通窍鼻炎方对慢性鼻窦炎患者体内Foxa2、黏蛋白MUC5AC、HIF-1α水平的影响[J].陕西中医,2018,39(8):1105-1108.
[5] HAN J K,BACHERT C,FOKKENS W,et al.Mepolizumab for chronic rhinosinusitis with nasal polyps(SYNAPSE):A randomised double-blind placebo-controlledphase 3 trial[J].Lancet Respir Med,2021,9(10):1141-1153.
[6] 王彬,金锐,刘静,等.过敏性鼻炎不同证型治疗方的药味配伍共性特点研究[J].医药导报,2023,42(4):488-495.
[7] 林曼青,周敏,陈腾宇,等.中药鼻腔冲洗治疗慢性鼻窦炎术后有效性和安全性的Meta分析[J].山东大学耳鼻喉眼学报,2022,36(3):209-225.
[8] 王振鹏.中西医结合治疗儿童慢性鼻窦炎临床观察[J].光明中医,2014,29(9):1914-1915.
[9] KLINGLER A I,STEVENS W W,TAN B K,et al.Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps[J].Journal Allergy Clin Immunol,2021,147(4):1306-1317.
[10] 刘铮,方彩珊,毛淑娴,等.基于数据挖掘探究阮岩治疗慢性鼻窦炎的用药规律[J].山东大学耳鼻喉眼学报,2022,36(3):202-208.
[11] WANG W,XU Y,WANG L,et al.Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic rhinosinusitis[J].Nat Immunol,2022,23(10):1484-1494.
[12] 朱旭利,李安,高静,等.不伴下呼吸道疾病的慢性鼻窦炎患者肺功能损害相关性分析[J].陕西医学杂志,2023,52(8):1029-1033.
[13] 李社锋,王勇,钱芝卫,等.辛芷通窍颗粒联合克拉霉素治疗慢性鼻窦炎的临床观察[J].中国中西医结合耳鼻咽喉科杂志,2018,26(6):436-439.
[14] 何灶娣,曾仲意,曾林生.辛芷通窍方联合西药治疗急性鼻-鼻窦炎临床观察[J].中国中医急症,2021,30(12):2173-2175.
[15] 于士龙,王思琪,崔思娇,等.辛芷通窍丸的质量标准研究[J].西北药学杂志,2018,33(2):167-170.
[16] BACHERT C,SOUSA A R,HAN J K,et al.Mepolizumab for chronic rhinosinusitis with nasal polyps:Treatment efficacy by comorbidity and blood eosinophil count[J].Journal Allergy Clin Immunol,2022,149(5):1711-1721.
[17] 张淑霞,卫平存,王刚,等.鼻内镜术前应用枸地氯雷他定对慢性鼻窦炎的治疗效果及对患者嗅觉功能和鼻黏膜形态的影响[J].现代生物医学进展,2023,23(15):2894-2898.
[18] LOURIJSEN E S,REITSMA S,VLEMING M,et al.Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps:A multicentre randomised controlled trial[J].Lancet Respir Med,2022,10(4):337-346.
[19] SHAO L H,ZHU L,WANG M,et al.Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance[J].Int Journal Mol Med,2023,52(2):1-17.
[20] 王睿智,朱锦祥,方彩珊,等.脂多糖通过NLRP3诱导并促进慢性鼻窦炎人鼻黏膜上皮细胞焦亡[J].免疫学杂志,2023,39(5):409-419.
[21] AYDIN P,AKSAKALLI Z B,CIVELEK M S,et al.The melatonin agonist ramelteon attenuates bleomycin-induced lung fibrosis by suppressing the NLRP3/TGF-β1/HMGB1 signaling pathway[J].Adv Med Sci,2023,68(2):322-331.
[22] FEI L,ZHANG N,ZHANG J.Mechanism of miR-126 in hypoxia-reoxygenation-induced cardiomyocyte pyroptosis by regulating HMGB1 and NLRP3 inflammasome[J].Immunopharmacol Immunotoxicol,2022,44(4):500-509.
[23] CAI J,CHEN X,LIU X,et al.AMPK:The key to ischemia-reperfusion injury[J].Journal Cell Physiol,2022,237(11):4079-4096.
[24] 李特,宋天喜,秦喜昕,等.苦参碱通过调控HMGB1/NLRP3信号途径抑制慢性鼻-鼻窦炎小鼠炎症反应[J].广东药科大学学报,2022,38(5):25-32.
[25] SUN T,XU W,WANG J,et al.Paeonol ameliorates diabetic erectile dysfunction by inhibiting HMGB1/RAGE/NF-κB pathway[J].Andrology,2023,11(2):344-357.
[26] 刘一潼,周穗子.NLRP3炎症小体在慢性鼻窦炎和变应性鼻炎中的研究进展[J].山东大学耳鼻喉眼学报,2022,36(3):142-146,153.

相似文献/References:

[1]张竞飞,俞鹏飞,安月鹏,等.吉雷开窍汤联合西药治疗对胆腑郁热型慢性鼻窦炎患儿鼻腔菌群和鼻腔功能的影响[J].陕西中医,2025,46(4):472.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.008]
　ZHANG Jingfei,YU Pengfei,AN Yuepeng,et al.Effect of Jilei Kaiqiao decoction combined with western medicine treatment on nasal flora and nasal function in patients with bile-vessel depression-heat type chronic sinusitis[J].,2025,46(3):472.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.008]

备注/Memo

备注/Memo:
基金项目:河北省中医药管理局科研计划项目(2018036)
更新日期/Last Update: 2024-03-08